{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:40:50Z","timestamp":1792197650060,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100015050","name":"Sociedad Espa\u00f1ola de Epilepsia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024207","name":"Angelini Pharma Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01067-y","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:49Z","timestamp":1792195009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positioning Cenobamate in the Treatment Algorithm of Focal Epilepsy: Seizure Control and Benefits Beyond Seizures"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-3316","authenticated-orcid":false,"given":"Manuel","family":"Toledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garc\u00eda-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jes\u00fas","family":"Rodr\u00edguez-Uranga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Serratosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"3","key":"1067_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279\u201386. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3949.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1067_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069\u201377. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02397.x.","journal-title":"Epilepsia"},{"key":"1067_CR3","doi-asserted-by":"publisher","unstructured":"Cerulli Irelli E, Roberti R, Borioni MS, et al. Comparative effectiveness of brivaracetam, cenobamate, lacosamide, and perampanel in focal epilepsy. JAMA Neurol. 2026;83(4):320\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2025.5625.","DOI":"10.1001\/jamaneurol.2025.5625"},{"issue":"2","key":"1067_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ane.13257","volume":"142","author":"JJ Halford","year":"2020","unstructured":"Halford JJ, Edwards JC. Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand. 2020;142(2):91\u2013107. https:\/\/doi.org\/10.1111\/ane.13257.","journal-title":"Acta Neurol Scand"},{"key":"#cr-split#-1067_CR5.1","unstructured":"European Medicines Agency. Meeting highlights: Pharmacovigilance Risk Assessment Committee (PRAC), 7-10 April 2026. Amsterdam: EMA"},{"key":"#cr-split#-1067_CR5.2","unstructured":"2026. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-april-2026. Accessed 2026 Aug 18."},{"issue":"1","key":"1067_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348. https:\/\/doi.org\/10.1016\/S1474-4422(19)30399-0.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1067_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/epi4.12959","volume":"9","author":"JJ Rodr\u00edguez-Uranga","year":"2024","unstructured":"Rodr\u00edguez-Uranga JJ, S\u00e1nchez-Caro JM, Hariramani Ramchandani R. Treatment simplification to optimize cenobamate effectiveness and tolerability: a real-world retrospective study in Spain. Epilepsia Open. 2024;9(4):1345\u201356. https:\/\/doi.org\/10.1002\/epi4.12959.","journal-title":"Epilepsia Open"},{"key":"1067_CR8","doi-asserted-by":"publisher","unstructured":"Villanueva V, Serratosa JM, Fern\u00e1ndez-Cabrera A, et al. FREEDOM study: real-life outcomes of cenobamate in different lines of treatment. Epilepsia. 2026;67(5):2177\u201389. https:\/\/doi.org\/10.1002\/epi.70106.","DOI":"10.1002\/epi.70106"},{"issue":"3","key":"1067_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2174\/1871527321666220113110044","volume":"22","author":"MA Barbieri","year":"2023","unstructured":"Barbieri MA, Perucca E, Spina E, Rota P, Franco V. Cenobamate: a review of its pharmacological properties, clinical efficacy and tolerability profile in the treatment of epilepsy. CNS Neurol Disord Drug Targets. 2023;22(3):394\u2013403. https:\/\/doi.org\/10.2174\/1871527321666220113110044.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"6","key":"1067_CR10","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/epi.17564","volume":"64","author":"P Klein","year":"2023","unstructured":"Klein P, Krauss GL, Steinhoff BJ, Devinsky O, Sperling MR. Failure to use new breakthrough treatments for epilepsy. Epilepsia. 2023;64(6):1458\u201365. https:\/\/doi.org\/10.1111\/epi.17564.","journal-title":"Epilepsia"},{"key":"1067_CR11","unstructured":"Sociedad Espa\u00f1ola de Epilepsia (SEEP). Resultados de la encuesta sobre la influencia de los MACs de 4\u00aa generaci\u00f3n en la catalogaci\u00f3n de epilepsia focal farmacorresistente. Madrid: SEEP. https:\/\/seepnet.es\/node\/332. Accessed 2026 Aug 18."},{"issue":"3","key":"1067_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/epi4.12757","volume":"8","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Santos-Carrasco D, Cabezudo-Garc\u00eda P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open. 2023;8(3):918\u201329. https:\/\/doi.org\/10.1002\/epi4.12757.","journal-title":"Epilepsia Open"},{"key":"1067_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2026.110960","volume":"179","author":"JM Serratosa","year":"2026","unstructured":"Serratosa JM, Gil-Nagel A, Toledo M, et al. Seizure-free days as a clinical outcome measure of reduced epilepsy burden: 5-year outcomes with cenobamate treatment. Epilepsy Behav. 2026;179:110960. https:\/\/doi.org\/10.1016\/j.yebeh.2026.110960.","journal-title":"Epilepsy Behav"},{"key":"1067_CR14","doi-asserted-by":"publisher","unstructured":"Lattanzi S, Dono F, D\u2019Orsi G, et al. Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: interim results after 24-week observational period from the BLESS study. Epilepsia. 2025;66(7):2239\u201352. https:\/\/doi.org\/10.1111\/epi.18357.","DOI":"10.1111\/epi.18357"},{"issue":"1","key":"1067_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/epi.17134","volume":"63","author":"JW Sander","year":"2022","unstructured":"Sander JW, Rosenfeld WE, Halford JJ, Steinhoff BJ, Biton V, Toledo M. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia. 2022;63(1):139\u201349. https:\/\/doi.org\/10.1111\/epi.17134.","journal-title":"Epilepsia"},{"key":"1067_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110464","volume":"170","author":"M Toledo","year":"2025","unstructured":"Toledo M, Abraira L, L\u00f3pez-Maza S, et al. Steps towards seizure freedom with the use of cenobamate. Epilepsy Behav. 2025;170:110464. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110464.","journal-title":"Epilepsy Behav"},{"issue":"Suppl 1","key":"1067_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/epi.18303","volume":"66","author":"P Klein","year":"2025","unstructured":"Klein P. Cenobamate efficacy in specific populations. Epilepsia. 2025;66(Suppl 1):29\u201337. https:\/\/doi.org\/10.1111\/epi.18303.","journal-title":"Epilepsia"},{"key":"1067_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241256733","volume":"17","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff BJ, Ben-Menachem E, Klein P, et al. Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations. Ther Adv Neurol Disord. 2024;17:17562864241256733. https:\/\/doi.org\/10.1177\/17562864241256733.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"1067_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200151","volume":"10","author":"PJ Serrano-Castro","year":"2023","unstructured":"Serrano-Castro PJ, Rodr\u00edguez-Uranga JJ, Cabezudo-Garc\u00eda P, et al. Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-GAD65 antibodies. Neurol Neuroimmunol Neuroinflamm. 2023;10(6):e200151. https:\/\/doi.org\/10.1212\/NXI.0000000000200151.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"17","key":"1067_CR20","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","volume":"96","author":"B Sultana","year":"2021","unstructured":"Sultana B, Panzini MA, Veilleux Carpentier A, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96(17):805\u201317. https:\/\/doi.org\/10.1212\/WNL.0000000000011839.","journal-title":"Neurology"},{"issue":"3","key":"1067_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/epi4.12936","volume":"9","author":"M Carre\u00f1o","year":"2024","unstructured":"Carre\u00f1o M, Gil-Nagel A, Serratosa JM, Toledo M, Rodr\u00edguez-Uranga JJ, Villanueva V. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures. Epilepsia Open. 2024;9(3):1051\u20138. https:\/\/doi.org\/10.1002\/epi4.12936.","journal-title":"Epilepsia Open"},{"issue":"3","key":"1067_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1684\/epd.2015.0751","volume":"17","author":"E Beghi","year":"2015","unstructured":"Beghi E, Giussani G, Sander JW. The natural history and prognosis of epilepsy. Epileptic Disord. 2015;17(3):243\u201353. https:\/\/doi.org\/10.1684\/epd.2015.0751.","journal-title":"Epileptic Disord"},{"issue":"4","key":"1067_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13002-6","volume":"272","author":"X Xu","year":"2025","unstructured":"Xu X, Sha L, Basang S, et al. Mortality in patients with epilepsy: a systematic review. J Neurol. 2025;272(4):291. https:\/\/doi.org\/10.1007\/s00415-025-13002-6.","journal-title":"J Neurol"},{"key":"1067_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.seizure.2020.10.009","volume":"83","author":"AM Kanner","year":"2020","unstructured":"Kanner AM, Helmstaedter C, Sadat-Hossieny Z, Meador K. Cognitive disorders in epilepsy I: clinical experience, real-world evidence and recommendations. Seizure. 2020;83:216\u201322. https:\/\/doi.org\/10.1016\/j.seizure.2020.10.009.","journal-title":"Seizure"},{"issue":"12","key":"1067_CR25","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1007\/s00415-023-11958-x","volume":"270","author":"R Toledano","year":"2023","unstructured":"Toledano R, Villanueva V, Toledo M, Sabaniego J, P\u00e9rez-Domper P. Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis. J Neurol. 2023;270(12):5945\u201357. https:\/\/doi.org\/10.1007\/s00415-023-11958-x.","journal-title":"J Neurol"},{"key":"1067_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110440","volume":"169","author":"AD Jimenez","year":"2025","unstructured":"Jimenez AD, Toghramadjian I, Okafor CM, et al. Cenobamate and pregnancy: a single level 4 epilepsy center experience. Epilepsy Behav. 2025;169:110440. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110440.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1067_CR27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/epi.70006","volume":"67","author":"JM S\u00e1nchez-Caro","year":"2026","unstructured":"S\u00e1nchez-Caro JM, Hariramani Ramchandani R, Maestro Saiz I, Rodr\u00edguez Uranga JJ. Impact of long-term treatment with cenobamate on concomitant usage of antiseizure medications: a real-world retrospective study in Spain. Epilepsia. 2026;67(3):1221\u201334. https:\/\/doi.org\/10.1111\/epi.70006.","journal-title":"Epilepsia"},{"key":"1067_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.seizure.2025.05.016","volume":"131","author":"T Paul","year":"2025","unstructured":"Paul T, Nei M. Cenobamate use in pregnancy: a case report. Seizure. 2025;131:26\u20138. https:\/\/doi.org\/10.1016\/j.seizure.2025.05.016.","journal-title":"Seizure"},{"key":"1067_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2026.111090","volume":"181","author":"M Toledo","year":"2026","unstructured":"Toledo M, Garc\u00e9s-Pellejero M, L\u00f3pez-Maza S, et al. Self-reported quality of life outcomes after cenobamate initiation. Epilepsy Behav. 2026;181:111090. https:\/\/doi.org\/10.1016\/j.yebeh.2026.111090.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1067_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","volume":"22","author":"E Perucca","year":"2023","unstructured":"Perucca E, Perucca P, White HS, Wirrell EC. Drug resistance in epilepsy. Lancet Neurol. 2023;22(8):723\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(23)00151-5.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1067_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","volume":"12","author":"AM Kanner","year":"2016","unstructured":"Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol. 2016;12(2):106\u201316. https:\/\/doi.org\/10.1038\/nrneurol.2015.243.","journal-title":"Nat Rev Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01067-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01067-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01067-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:51Z","timestamp":1792195011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01067-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":32,"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01067-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"31 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following authors\/faculty members, all specialists in epilepsy, declare that they received consulting fees, advisory board, speaker honoraria, research grants, travel support from: Manuel Toledo: UCB Pharma, Jazz, BIAL, SK-life, BIAL, EISAI, Neuraxpharm, Desitin, Knight, Eurofarma. Jos\u00e9 Serratosa: Angelini, UCB Pharma, Jazz, BIAL, SK-life, BIAL, EISAI, Mar Carre\u00f1o: Angelini, UCB Pharma, Jazz, BIAL, SK-life, BIAL, EISAI. Vicente Villanueva: Angelini, UCB Pharma, Jazz, BIAL, SK-life, BIAL, EISAI. Juan Rodr\u00edguez Uranga: Angelini, UCB Pharma, Jazz, BIAL, SK-life, BIAL, EISAI. Irene Garc\u00eda Morales: Angelini, UCB Pharma, Jazz, BIAL, SK-life, BIAL, EISAI.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for this study was obtained from Spanish Epilepsy Society (Spanish Chapter of the International League Against Epilepsy [ILAE];\n                      \n                      ) according to the evaluation of the steering committee on September 17, 2025. The study did not involve any active research with the involvement of patients or data, so it was exempt from institutional review board (IRB) approval or consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}